ArticleThe journal of headache and pain2019
Burden of headache disorders in China, 1990-2017: findings from the Global Burden of Disease Study 2017.
Article in The journal of headache and pain, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 100 citations in OpenAlex.
- Prevalence of Migraine and Other Types of Primary Headache in China: A Systematic Review and Meta-Analysis.Neuroepidemiology · 2026Pooled it
- Risk of dry eye in headache patients: a systematic review and meta-analysis.Annals of medicine · 2022Pooled it
- Efficacy and Safety of Oral Chinese Herbal Medicine for Migraine: A Systematic Review and Meta-Analyses Using Robust Variance Estimation Model.Frontiers in neurology · 2022Pooled it
- Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial.The journal of headache and pain · 2024Trial
- Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study.The journal of headache and pain · 2022Trial
- Prevalence and burden of neurological diseases in China: An analysis from the Global Burden of Disease Study 2021.Chinese medical journal · 2026Article
- Cost-utility analysis of erenumab preventive treatment for chronic migraine in China.Frontiers in public health · 2026Article
- A Phase 1 Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Intranasal Dose of Zavegepant in Healthy Chinese Adults.Clinical pharmacology in drug development · 2026Article
- An analysis of the burden of migraine and tension-type headache across the global, China, the United States, India and Japan.Frontiers in pain research (Lausanne, Switzerland) · 2025Article
- Health Technology Assessment: Evaluation of 8 CGRP-Targeted Therapy Drugs for the Treatment of Migraine.Drug design, development and therapy · 2025Article
- Consulting, diagnosis and treatment patterns in migraine: results from the Migraine in Poland cross-sectional survey.Therapeutic advances in neurological disorders · 2025Article
- Prevalence and risk factors of headache in Chinese with stroke: a cross-sectional study based on CHARLS.The journal of headache and pain · 2024Article
- Exploring the efficacy of acupuncture for tension-type headache: a literature review and insights from traditional Chinese medicine.Journal of oral & facial pain and headache · 2024Review
- Migraine headache (MH) classification using machine learning methods with data augmentation.Scientific reports · 2024Article
- Identification of genetic susceptibility for Chinese migraine with depression using machine learning.Frontiers in neurology · 2024Article
- Cost-effectiveness analysis of rimegepant for on-demand acute treatment of migraine in China.Frontiers in neurology · 2024Article
- Health equity, care access and quality in headache - part 2.The journal of headache and pain · 2023Review
- Trends in migraine incidence among women of childbearing age from 1990 to 2019 and the prediction for 2030: an analysis of national data in China.The journal of headache and pain · 2023Article
- Effectiveness and safety of Xuefu Zhuyu oral liquid on -stagnation and blood-stasis pattern in patients with stable angina, tension-type headache and primary dysmenorrhea: rationale and design of a master protocol.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2023Article
- Global, regional, and national time trends in incidence for migraine, from 1990 to 2019: an age-period-cohort analysis for the GBD 2019.The journal of headache and pain · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundHeadache has emerged as a global public health concern. However, little is known about the burden from headache disorders in China. The aim of this work was to quantify the spatial patterns and temporal trends of burden from headache disorders in China.
methodsFollowing the general analytic strategy used in the 2017 Global Burden of Disease study, we analyzed the prevalence and years lived with disability (YLDs) of headache and its main subcategories, including migraine and tension-type headache (TTH), by age, sex, year and 33 province-level administrative units in China from 1990 to 2017.
resultsAlmost 112.4 million individuals were estimated to have headache disorders in 1990 in China, which rose to 482.7 million in 2017. The all-age YLDs increased by 36.2% from 1990 to 2017. Migraine caused 5.5 million YLDs, much higher than TTH (1.1 million) in 2017. The age-standardized prevalence and YLDs rate of headache remained stable and high in 2017 compared with 1990, respectively. The proportion of total headache YLDs in all diseases increased from 1990 to 2017 by 5.4%. A female preponderance was observed for YLDs and the YLDs were mainly in people aged 20~54 years.
conclusionsHeadache remains a huge health burden in China from 1990 to 2017, with prevalence and YLDs rates higher in eastern provinces than western provinces. The substantial increase in headache cases and YLDs represents an ongoing challenge in Chinese population. Our results can help shape and inform headache research and public policy throughout China, especially for females and middle-aged people.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.